scholarly journals The Risk of Cardiac-related Mortality in Stage IIIA-N2 Non-small Cell Lung Cancer: Analysis of the Surveillance, Epidemiology, and End Results Database

2020 ◽  
Author(s):  
Xin Sun ◽  
Yu Men ◽  
Jianyang Wang ◽  
Yongxing Bao ◽  
Xu Yang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Risk Model ◽  
The United States ◽  
Small Cell ◽  
Seer Database ◽  
Small Cell Lung ◽  
Related Mortality ◽  
End Results

Abstract Background: We aimed to investigate the association between postoperative radiotherapy (PORT) and cardiac-related mortality for patients with ⅢA-N2 non-small cell lung cancer (NSCLC) by the Surveillance, Epidemiology, and End Results (SEER) database.Methods: The United States (US) population based SEER database were queried for cardiac-related mortality among patients with ⅢA-N2 NSCLC. Cardiac-related mortality was compared between PORT and Non-PORT group. Accounting for mortality from other causes, Gray’s test compared cumulative incidences of cardiac-related mortality between both groups. Univariate and multivariate analysis were performed using the competing risk model.Results: From 1988 to 2016, 7290 patients met the inclusion criteria: 3386 patients treated with PORT and 3904 patients treated with Non-PORT. The 5-year overall incidence of cardiac-related mortality was 3.01% in PORT group and 3.26% in Non-PORT group. Older age, male sex, squamous cell lung cancer, earlier year of diagnosis and earlier T stage were independent adverse factors for cardiac-related mortality. However, PORT use wasn’t associated with an increase in the hazard for cardiac-related mortality (subdistribution hazard ratio [SHR]=0.99, 95% confidence interval [95% CI], 0.78–1.24, p=0.91). When evaluating cardiac-related mortality in each time period, the overall incidence of cardiac-related mortality was decreased over time. There were no statistically significant differences based on PORT use in all time periods.Conclusions: With a median follow-up of 25 months, no significant differences were found in cardiac-related mortality between PORT and Non-PORT for ⅢA-N2 NSCLC patients.

scholarly journals Outcomes for Surgery in Stage IA Large Cell Lung Neuroendocrine Compared With Other Types of Non-Small Cell Lung Cancer: A Propensity Score Matching Study Based on the Surveillance, Epidemiology, and End Results (SEER) Database

2020 ◽  
Vol 10 ◽  
Author(s):  
Liqing Zou ◽  
Tiantian Guo ◽  
Luxi Ye ◽  
Yue Zhou ◽  
Li Chu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Large Cell ◽  
Small Cell ◽  
Stage I ◽  
Seer Database ◽  
Small Cell Lung ◽  
Stage Ia ◽  
End Results

BackgroundPulmonary large cell neuroendocrine cancer (LCNEC) is commonly classified as non-small cell lung cancer (NSCLC). Even for stage I disease, after surgery the survival is always poor, but clinical research on LCNEC is scant and always with unsatisfying sample sizes. Thus, we conduct the first study using the Surveillance, Epidemiology, and End Results (SEER) database to compare survival after surgery between stage I LCNEC and other types of NSCLC.MethodsFrom 2004 to 2016, 473 patients with stage IA LCNEC, 17,669 patients with lung adenocarcinoma (LADC) and 8,475 patients with lung squamous cell cancer (LSCC), all treated with surgery were identified. In addition, 1:1 PSM was used, and overall (OS) and cancer-specific survival (CSS) between groups were compared.ResultsThe 5-year OS rates and CSS rates for LCNEC were 52.5% and 81.5%, respectively. Overall, both OS and CSS were significantly superior for stage IA LADC than LCNEC (for OS: HR 0.636, 95% CI 0.568-0.712; for CSS: HR 0.688, 95% CI 0.561–0.842, LCNEC as reference), while comparable for LSCC with LCNEC (for OS: HR 0.974, 95% CI 0.869–1.091; for CSS: HR 0.907, 95% CI 0.738–1.115). PSM generated 471 pairs when LCNEC was compared with LADC and both OS and CSS were significantly better in LADC than LCNEC (for OS: HR 0.580, 95% CI 0.491–0.686; for CSS: HR 0.602, 95% CI 0.446–0.814). Of note, for the subgroup of patients ≤ 65 years old, HRs for both OS and CSS were lower (for OS: HR 0.470; for CSS: HR 0.482). As for comparison between LCNEC and LSCC, PSM generated 470 pairs. Differently, only CSS was significantly superior in LSCC than LCNEC (HR 0.563, 95% CI 0.392–0.807), while OS was not. Further grouping by age showed only CSS between two groups for patients with age ≤ 65 years old was significantly different (P = 0.006).ConclusionsWe report the first survival comparison after surgery between stage IA LCNEC and other types of NSCLC by SEER database and PSM. Our results demonstrated after surgery, stage IA LCNEC was worse in survival, especially compared to LADC. Extra clinical care should be paid, especially for younger patients. More studies investigating adjuvant therapy are warranted.

Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database

2006 ◽  
Vol 24 (28) ◽  
pp. 4539-4544 ◽  
Author(s):  
Ramaswamy Govindan ◽  
Nathan Page ◽  
Daniel Morgensztern ◽  
William Read ◽  
Ryan Tierney ◽  
...  
Keyword(s):  
United States ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
The United States ◽  
Small Cell ◽  
Small Cell Lung ◽  
Modest Improvement ◽  
Histologic Subtype ◽  
End Results

Purpose Small-cell lung cancer (SCLC) is a histologic subtype of lung cancer with a distinct biology and clinical course. It has been observed that the incidence of SCLC has been decreasing over the last several years. Methods We used the Surveillance, Epidemiologic, and End Results (SEER) database to determine the incidence of SCLC over the last 30 years. In addition, we sought to determine sex- and stage-based differences in the incidence and survival of SCLC among a proportion of reported cases of lung cancer over the last 30 years (1973 to 2002). Joinpoint analyses were applied to test the trends in annual percentage change for statistical significance. Results The proportion of SCLC (among all lung cancer histologic types) decreased from 17.26% in 1986 to 12.95% in 2002. Of all patients with SCLC, the proportion of women with SCLC increased from 28% in 1973% to 50% in 2002. A modest but statistically significant improvement in 2- and 5-year survival was noted among both limited-stage SCLC and extensive-stage SCLC cohorts during the study period. Conclusion Our analysis indicates that the incidence of SCLC is decreasing in the United States, and only modest improvements have been seen in survival over the last 30 years. Possible explanations for the decreasing incidence include the decrease in the percentage of smokers and the change to low-tar filter cigarettes. Despite trends toward modest improvement in survival, the outcome remains very poor.

Sign in / Sign up

Export Citation Format

Share Document